New Delhi, 18 December 2021

As per news report of NDTV, The team, including researchers from the University of Birmingham and the University of Oxford, UK, tested namilumab - an antibody already in late-stage trials to treat rheumatoid arthritis - in patients hospitalised with COVID-19 pneumonia. The patients were receiving 'usual' care, as well as having high levels in their blood of a marker of inflammation known as C reactive protein (CRP). CRP levels rise when there is inflammation in the body, and elevated levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19, the researchers said. "Our research has provided important proof-of-concept evidence that namilumab reduces inflammation in hospitalised patients with COVID-19 pneumonia," said Ben Fisher, co-chief investigator of the trial at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust (UHB).

Source - NDTV

Read More >>